Shots:
The US FDA has granted RMAT designation to GLPG5101 for the r/r mantle cell lymphoma (MCL)
Designation was supported by P-I/II (ATALANTA-1) trial assessing GLPG5101 [50×106 (DL1), 110×106 (DL2) & 250×106 (DL3)] in r/r B-cell Non-Hodgkin Lymphoma pts, incl. those with MCL
Trial demonstrated superior ORR & CR rate as well as favorable safety…
